Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Cenobamate

            Therapeutic Area: Neurology Product Name: Xcopri

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 10, 2020

            Details:

            The Phase 3 trial is a randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of cenobamate as an adjunctive therapy in subjects with partial-onset seizures, with an optional open-label extension.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Cenobamate

            Therapeutic Area: Neurology Product Name: Xcopri

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Undisclosed

            Deal Size: $800.0 million Upfront Cash: Undisclosed

            Deal Type: Public Offering June 19, 2020

            Details:

            SK Biopharmaceuticals Co Ltd priced its initial public offering on Friday at the top of its indicative range, aiming to raise 959 billion won ($794 million) in South Korea's biggest IPO in three years.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Cenobamate

            Therapeutic Area: Neurology Product Name: Xcopri

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Undisclosed

            Deal Size: $822.0 million Upfront Cash: Undisclosed

            Deal Type: Public Offering June 15, 2020

            Details:

            Proceeds will be used accelerate further advancement of the Company's pipeline which include, cenobamate, solriamfetol and among others.